Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953038 | 0.95 | TACR1 (0.41) | TACR1MMP2MMP9CYP2D6MEN1 | |
| SCHEMBL13904515 | 0.95 | TACR1 (0.41) | TACR1MMP2MMP9CYP2D6MEN1 | |
| SCHEMBL4062789 | 0.89 | TACR1 (0.44) | TACR1MMP2MMP9CYP2D6TACR3 | |
| SCHEMBL4216399 | 0.89 | TACR1 (0.42) | TACR1MMP2MMP9TACR3MEN1 | |
| SCHEMBL3947792 | 0.88 | MMP9 (0.43) | TACR1MMP2MMP9CYP2D6TACR3 | |
| SCHEMBL13904509 | 0.88 | MMP9 (0.43) | TACR1MMP2MMP9CYP2D6TACR3 | |
| SCHEMBL4055562 | 0.83 | TACR1 (0.46) | TACR1MMP2MMP9TACR3MEN1 | |
| SCHEMBL4145231 | 0.81 | MMP2 (0.36) | TACR1MMP2MMP9CYP2D6MEN1 | |
| SCHEMBL13948961 | 0.81 | CDK4 (0.46) | TACR1MEN1KMT2A | |
| SCHEMBL13904514 | 0.81 | KMT2A (0.47) | TACR1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | TACR1 167/4885MMP2 3861/4885MMP9 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.